{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:34:00Z","timestamp":1790310840105,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006136","name":"Fuel Cell Technologies Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biofilm"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioflm.2024.100252","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:50:58Z","timestamp":1735545058000},"page":"100252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants of Pseudomonas aeruginosa isolates in vitro within cystic fibrosis airway mucus"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-8410","authenticated-orcid":false,"given":"Rosana","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Margarida","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ol\u00edvia","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioflm.2024.100252_bib1","series-title":"Patient registry annual data report","year":"2019"},{"key":"10.1016\/j.bioflm.2024.100252_bib2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bioflm.2024.100252_bib3","series-title":"UK cystic fibrosis registry 2021 annual data report","year":"2022"},{"key":"10.1016\/j.bioflm.2024.100252_bib4","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiot (Basel, Switzerland)"},{"key":"10.1016\/j.bioflm.2024.100252_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/656788","article-title":"Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa","volume":"202","author":"Herrmann","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bioflm.2024.100252_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bioflm.2024.100252_bib7","series-title":"Antibiotic treatment for cystic fibrosis","year":"2009"},{"key":"10.1016\/j.bioflm.2024.100252_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9091874","article-title":"Current and emerging therapies to combat cystic fibrosis lung infections","volume":"9","author":"Manos","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.bioflm.2024.100252_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.02057","article-title":"Tolerance and persistence of Pseudomonas aeruginosa in biofilms exposed to antibiotics: molecular mechanisms, antibiotic strategies and therapeutic perspectives","volume":"11","author":"Soares","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1099\/mic.0.033993-0","article-title":"Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and\/or lasR mutants","volume":"156","author":"Ciofu","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.bioflm.2024.100252_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/thorax.58.9.794","article-title":"Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents","volume":"58","author":"Pitt","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.bioflm.2024.100252_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008439","article-title":"Pseudomonas aeruginosa exploits lipid a and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection","volume":"4","author":"Cigana","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bioflm.2024.100252_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00199-10","article-title":"Parallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo","volume":"1","author":"Huse","year":"2010","journal-title":"mBio"},{"key":"10.1016\/j.bioflm.2024.100252_bib14","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.1128\/JB.01147-08","article-title":"Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation","volume":"190","author":"Mena","year":"2008","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bioflm.2024.100252_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2018.10.003","article-title":"Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance","author":"Sousa","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib16","article-title":"What are the advantages of living in a community? A microbial biofilm perspective","author":"Dos Santos","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bioflm.2024.100252_bib17","doi-asserted-by":"crossref","DOI":"10.4155\/fmc.15.6","article-title":"Biofilm formation mechanisms and targets for developing antibiofilm agents","author":"Rabin","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bioflm.2024.100252_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.giec.2020.06.004","article-title":"Antimicrobial resistance","author":"Morrison","year":"2020","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"10.1016\/j.bioflm.2024.100252_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/1040841X.2019.1599813","article-title":"Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria","author":"Liu","year":"2019","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00441","article-title":"Fostering innovation in the treatment of chronic polymicrobial cystic fibrosis-associated infections exploring aspartic acid and succinic acid as ciprofloxacin adjuvants","volume":"10","author":"Silva","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1717160115","article-title":"Technologies to address antimicrobial resistance","author":"Baker","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bioflm.2024.100252_bib22","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399410001766","article-title":"Antibiotic adjuvants: multicomponent anti-infective strategies","author":"Kalan","year":"2011","journal-title":"Expet Rev Mol Med"},{"key":"10.1016\/j.bioflm.2024.100252_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13010071","article-title":"New antimicrobial strategies to treat multi-drug resistant infections caused by gram-negatives in cystic fibrosis","volume":"13","author":"Scoffone","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioflm.2024.100252_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JB.186.21.7312-7326.2004","article-title":"Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm","author":"Sauer","year":"2004","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bioflm.2024.100252_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu286","article-title":"pH-mediated potentiation of aminoglycosides kills bacterial persisters and eradicates in vivo biofilms","author":"Lebeaux","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bioflm.2024.100252_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.02429","article-title":"Glutathione enhances antibiotic efficiency and effectiveness of DNase I in disrupting Pseudomonas aeruginosa biofilms while also inhibiting pyocyanin activity, thus facilitating restoration of cell enzymatic activity, Confluence and Viability","volume":"8","author":"Das","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib27","series-title":"Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement","year":"2007"},{"key":"10.1016\/j.bioflm.2024.100252_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mimet.2007.11.010","article-title":"Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates","volume":"72","author":"Peeters","year":"2008","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.bioflm.2024.100252_bib29","first-page":"2146","article-title":"Insights into cystic fibrosis polymicrobial consortia: the role of species interactions in biofilm development, phenotype, and response to in-use antibiotics","volume":"7","author":"Magalh\u00e3es","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","article-title":"Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung","volume":"54","author":"Sriramulu","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2018.10.003","article-title":"Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance","author":"Sousa","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib32","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1038\/s41598-020-66082-x","article-title":"Evaluation of anti-biofilm activity of acidic amino acids and synergy with ciprofloxacin on Staphylococcus aureus biofilms","volume":"10","author":"Warraich","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bioflm.2024.100252_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/femsle\/fnv025","article-title":"Aspartate inhibits Staphylococcus aureus biofilm formation","volume":"362","author":"Yang","year":"2015","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.bioflm.2024.100252_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0099513","article-title":"An in vitro study on the effect of free amino acids alone or in combination with nisin on biofilms as well as on planktonic bacteria of Streptococcus mutans","volume":"9","author":"Tong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioflm.2024.100252_bib35","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/bit.27760","article-title":"The role of extracellular DNA in the formation, architecture, stability, and treatment of bacterial biofilms","volume":"118","author":"Panlilio","year":"2021","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.bioflm.2024.100252_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2021","article-title":"The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects","volume":"30","author":"Van den Bossche","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.bioflm.2024.100252_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(02)00152-7","article-title":"Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets","author":"Hassett","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bioflm.2024.100252_bib38","doi-asserted-by":"crossref","DOI":"10.2217\/fmb.10.125","article-title":"Pseudomonas aeruginosa biofilms in cystic fibrosis","author":"H\u00f8iby","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/bit.23046","article-title":"Mannitol-Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model","author":"Yang","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.bioflm.2024.100252_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-016-0333-y","article-title":"Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time","volume":"16","author":"Crull","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.bioflm.2024.100252_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123800","article-title":"Impact of Pseudomonas aeruginosa infection on patients with chronic inflammatory airway diseases","volume":"9","author":"Garcia-Clemente","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.bioflm.2024.100252_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1369264","article-title":"Editorial: synergistic combinatorial treatments to overcome antibiotic resistance","volume":"14","author":"Garza-Cervantes","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.bioflm.2024.100252_bib43","first-page":"274","article-title":"Antimicrobial and antibiofilm activity of D-amino acids combined with nanoparticles against Candida albicans","volume":"11","author":"Jasim","year":"2020","journal-title":"Sys Rev Pharm"},{"key":"10.1016\/j.bioflm.2024.100252_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2019.06.002","article-title":"Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms","author":"Yan","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bioflm.2024.100252_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: an emerging battleground in microbial communities","author":"Sharma","year":"2019","journal-title":"Antimicrob Resist Infect Control"}],"container-title":["Biofilm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207524000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207524000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T03:33:05Z","timestamp":1749871985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590207524000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":45,"alternative-id":["S2590207524000777"],"URL":"https:\/\/doi.org\/10.1016\/j.bioflm.2024.100252","relation":{},"ISSN":["2590-2075"],"issn-type":[{"value":"2590-2075","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants of Pseudomonas aeruginosa isolates in vitro within cystic fibrosis airway mucus","name":"articletitle","label":"Article Title"},{"value":"Biofilm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioflm.2024.100252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100252"}}